Join Our Mailing List Today!

NOTICE: Online ordering will be disabled 1/27-2/3. Learn More.

FUJIFILM Irvine Scientific Completes Construction of Bioprocessing Innovation and Collaboration Center in China

New center opens in Suzhou New District, China, to bring local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development

SANTA ANA, California, May 17, 2022: FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced the completion of its Innovation and Collaboration Center in Suzhou New District, China.

Construction of the new Innovation and Collaboration Center began in December 2021 and is now open to facilitate collaboration between experts and customers for the tailored design of upstream cell culture processes that can meet individual biomanufacturing needs. The new facility will provide the local resources and expertise needed to optimize cell culture media and associated workflows to support commercial production of new drugs in China’s rapidly expanding market.

Yutaka Yamaguchi, chairman and chief executive officer, FUJIFILM Irvine Scientific, commented: “We have seen significant investment and growth within China’s biopharmaceutical, vaccine, cell and gene therapy markets, bolstered by the government’s dedication to making more affordable drugs available. Consequently, we have prioritized the completion and opening of FUJIFILM Irvine Scientific’s Collaboration and Innovation Center, allowing us to expand our expertise throughout this rapidly expanding market and provide local assistance for developing customer-tailored cell culture media solutions and workflows to compliment any biomanufacturing needs.”

FUJIFILM Irvine’s new Suzhou center joins its existing network of optimization services offered by facilities across the USA and Japan.

Download Press Release (PDF)

Notes to Editors

FUJIFILM Irvine Scientific
FUJIFILM Irvine Scientific, Inc., is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivaled service and quality to scientists working in biopharmaceuticals, cell therapy, and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years, FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit:

Media Contacts

Lori Serles
FUJIFILM Irvine Scientific
Phone: (949) 261-7800 x145

Lily Jeffery
Zyme Communications
Phone: +44 (0)7891 477 378



© 2024 FUJIFILM Irvine Scientific. All rights reserved.